SYED ANWAR: Open Payments
NPI 1053314401 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$262 in 12 payments from 10 companies in 2025. Trend: 2023 $283 · 2024 $178 · 2025 $262
Food & beverage: $262
| Company | Payments | Amount |
|---|---|---|
| Neurelis, Inc. | 1 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| PFIZER INC. | 1 | $21 |
| SANOFI-AVENTIS U.S. LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
Products named: VALTOCO, SHINGRIX, CAPLYTA, UZEDY, GVOKE HYPOPEN, REXULTI, AIRSUPRA, ELIQUIS.
Industry payments across TX — which companies pay providers there.
